Last reviewed · How we verify
Placebo insulin icodec
Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.
Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.
At a glance
| Generic name | Placebo insulin icodec |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Long-acting basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin icodec is a novel insulin analog engineered with a fatty acid chain that enables once-weekly subcutaneous dosing through enhanced albumin binding and extended half-life. It mimics endogenous insulin's mechanism by activating insulin receptors on muscle, adipose, and hepatic cells to facilitate glucose homeostasis. The extended duration of action allows for flexible dosing intervals while maintaining stable glycemic control.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (PHASE3)
- A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes (PHASE1)
- A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes. (PHASE2)
- A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo insulin icodec CI brief — competitive landscape report
- Placebo insulin icodec updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI